Company intelligence / Profile preview

IGEN BIOLAB SL

Spain

Ownership: Private
Development stage: Other

Overview

Igen Biolab is conducting a phase II clinical trial in Spain for their compound 'Igen 1806', aimed at improving quality of life and survival in lung cancer patients. They are also developing other compounds for inflammatory and degenerative diseases[1].

Therapeutic areas: ImmunologyPsychiatryGastroenterologyOncologyNeurology
Modalities: Live biotherapeutic product therapyPostbiotic
Industry: Biotech

Beyond the preview

Go deeper on IGEN BIOLAB SL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGEN BIOLAB SL.

Explore the full profile